2019-nCoV Spike S1 Subunit
$350.00 – $1,500.00
|2019-nCoV Spike S1 Subunit
|95% or above
|coronavirus spike Protein, 2019-nCoV; cov spike Protein, 2019-nCoV; ncov RBD Protein, 2019-nCoV; ncov s1 Protein, 2019- nCoV; ncov s2 Protein, 2019-nCoV; novel coronavirus spike Protein, 2019-nCoV; RBD Protein, 2019-nCoV; S1 Protein, 2019-nCoV; S2 Protein, 2019-nCoV; Spike RBD Protein, 2019-nCoV
|A DNA sequence encoding the SARS-CoV-2 (2019-nCoV) spike protein S1 subunit (Val16-Arg685)
|<0.1 EU per ug of protein as determined by LAL method
|Coronavirus (2019-nCoV) isolate Wuhan-Hu-1
|Spike protein S1 subunit consists of 679 amino acids. Predicted molecular mass of 76.2 kD.
|For research use only
|Recombinant proteins are provided as frozen liquid and will be shipped out with dry ice.
|Stability and storage
|The protein is stable in a liquid state at -70℃ for 12 months. Avoid repeated freeze-thaw cycles.
The spike proteins are the crown like protrusions which are densely glycosylated as it contains 21 to 35 N-glycosylation sites. It recognizes the corresponding receptors on the human cells and then undergoes a structural change that allows the viral membrane to fuse with the cell membrane. The viral RNA then enters the host cell, gets copied producing more viruses in the host. The spike protein has two domain organization: N-terminal domain called as the S1 subunit recognizes and binds to the angiotensin-converting enzyme 2 (ACE2) which is expressed in lung tissue and a C-terminal S2 domain responsible for fusion. The S2 subunit is the most conserved region of the protein, whereas the S1 subunit diverges in sequence even among species of a single coronavirus. The S1 contains two subdomains, a N-terminal domain (NTD) and a C-terminal domain (CTD). Both are able to function as receptor binding domains (RBDs) and bind a variety of proteins and sugars. The NTDs and CTDs of the S1 subunit can bind host receptors or function as receptor binding domains (RBD). The spike protein of Covid-19 is 10-20 times more likely to bind on ACE2 receptors on the human cells as compared to the SARS virus from 2002. This enables the virus to be spread from person to person more rapidly than the SARS virus from 2002. The antibodies for SARS virus could not successfully bind to Covid-19 spike protein, which makes it more unique than other coronaviruses making the spike protein a very good target for the development of vaccines and the diagnostic kits.